Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Chidamide, and Azacitidine in Treatment-Naïve Stage I-II Extranodal NK/T-Cell Lymphoma
NCT07542912Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, tucidinostat, azacitidine in extranodal natural killer T cell lymphoma (ENKTL), sponsored by Sun Yat-sen University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sintilimabtucidinostatazacitidine
03
Conditions
extranodal natural killer T cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT07542912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542912.